Form 4: Tyra Biosciences CDO Sells Shares Under 10b5-1 Plan

Tyra Biosciences' Chief Discovery Officer, Daniel Bensen, sold 8,000 shares of common stock on January 12, 2026, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Daniel Bensen, Chief Discovery Officer of Tyra Biosciences, Inc., sold a total of 8,000 shares of common stock.
• The sales occurred on January 12, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on November 5, 2024.
• 6,983 shares were sold at a weighted average price of $28.442 per share, with actual prices ranging from $27.9083 to $28.84.
• An additional 1,017 shares were sold at a weighted average price of $29.0808 per share, with actual prices ranging from $28.9131 to $29.23.
• Following these transactions, Daniel Bensen beneficially owns 154,981 shares of Tyra Biosciences common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a Chief Discovery Officer is generally a neutral event when conducted under a pre-arranged Rule 10b5-1 plan, as it indicates a planned liquidity event rather than a reaction to new company developments.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new, non-public information.

Negatives

• An insider sale, even under a 10b5-1 plan, reduces the reporting person's direct ownership in the company.
• The sale of 8,000 shares by a Chief Discovery Officer could be perceived by some investors as a slight negative signal regarding future prospects, despite the 10b5-1 plan.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains solely to an insider's past stock transactions.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. Insider sales are common across all industries, particularly when executed under pre-arranged 10b5-1 plans, which are designed to allow insiders to sell shares without being accused of trading on material non-public information.

Comparison to Industry Standards

• This filing reports an insider stock sale under a Rule 10b5-1 plan, which is a standard practice for corporate insiders to manage their equity holdings. There are no specific company or project results to compare against global benchmarks or competitors within this filing.

Related Party Transactions

• The sale of common stock by Daniel Bensen, Chief Discovery Officer, constitutes a related party transaction as he is an insider of Tyra Biosciences, Inc.

Stakeholder Impact

• Shareholders: The sale slightly reduces the direct ownership stake of a key executive, which could be interpreted differently by investors, though the 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Key Dates

Recommendation

The filing details a routine insider sale executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not indicative of new material information and does not provide a strong basis for a 'buy' or 'sell' recommendation. Investors should continue to 'hold' and evaluate the company based on its fundamental performance, pipeline developments, and broader market conditions rather than this planned insider transaction.

Keywords

Tyra Biosciences, TYRA, Form 4, Insider Trading, Stock Sale, Daniel Bensen, Chief Discovery Officer, 10b5-1 Plan, Biotechnology, SEC Filing